474 related articles for article (PubMed ID: 18779539)
1. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
4. Exploring multi-targeting strategies for the treatment of gliomas.
Omuro AM
Curr Opin Investig Drugs; 2008 Dec; 9(12):1287-95. PubMed ID: 19037835
[TBL] [Abstract][Full Text] [Related]
5. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
7. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
8. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
9. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and gliomas: current issues and development of surrogate markers.
Jouanneau E
Neurosurgery; 2008 Jan; 62(1):31-50; discussion 50-2. PubMed ID: 18300890
[TBL] [Abstract][Full Text] [Related]
11. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
14. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Mendel DB; Laird AD; Smolich BD; Blake RA; Liang C; Hannah AL; Shaheen RM; Ellis LM; Weitman S; Shawver LK; Cherrington JM
Anticancer Drug Des; 2000 Feb; 15(1):29-41. PubMed ID: 10888034
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
19. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
20. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Sathornsumetee S; Hjelmeland AB; Keir ST; McLendon RE; Batt D; Ramsey T; Yusuff N; Rasheed BK; Kieran MW; Laforme A; Bigner DD; Friedman HS; Rich JN
Cancer Res; 2006 Sep; 66(17):8722-30. PubMed ID: 16951188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
